Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 21 versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 21 versus MIUDELLA.
BALZIVA-21 vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
BALZIVA-21 is administered 150 mg orally twice daily.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive